Manina, G.Pasca, M. R.Buroni, S.De Rossi, E.Riccardi, G.2011-12-162011-12-162011-12-16201010.2174/092986710791959693https://infoscience.epfl.ch/handle/20.500.14299/75303WOS:000280524500010Tuberculosis is still a leading cause of death in developing countries and a resurgent disease in developed countries. The selection and soaring spread of Mycobacterium tuberculosis multidrug-resistant (MDR-TB) and extensively drug-resistant strains (XDR-TB) is a severe public health problem. Currently, there is an urgent need of new drugs for tuberculosis treatment, with novel mechanisms of action and, moreover, the necessity to identify new drug targets.Mycobacterium tuberculosisRv3790 (DprE1)cellular targetcell wallnew drugsCell-WallResistant TuberculosisCurrent ChallengesAtp SynthaseD-ArabinoseBiosynthesisStrategiesGenesBenzothiazinonesAntibioticsDecaprenylphosphoryl-beta-D-Ribose 2 '-Epimerase from Mycobacterium tuberculosis is a Magic Drug Targettext::journal::journal article::review article